Marc Carrier: Important New Data From the API-CAT Trial on Recurrent VTE During Extended Apixaban Therapy
Marc Carrier, Professor at Ottawa Hospital Research Institute, shared on LinkedIn about a recent article by Isabelle Mahé et al, published in Circulation, adding:
”Exciting results presented by Prof Isabelle Mahé at the International Society on Thrombosis and Haemostasis (ISTH) 2026 Congress in Paris, with simultaneous publication in Circulation.
Key findings from this pre-specified ancillary analysis of the API-CAT trial include:
- Recurrent VTE during extended apixaban therapy was uncommon, occurring in only 2.5% of 1,766 patients over 12 months.
- The risk of recurrence differed by cancer type, with the highest incidence observed in gastrointestinal cancers (excluding colorectal).
- The index VTE strongly predicted the pattern of recurrence. Patients presenting initially with PE were most likely to recur with PE, while those with isolated DVT recurred exclusively with DVT.
- Despite its low frequency, recurrent VTE carried a very poor short-term prognosis, with 50% mortality occurring within a median of just 24 days following recurrence.”
Title: Prognosis of Recurrent Venous Thromboembolism During Extended Apixaban Therapy for Cancer-Associated Thrombosis: Insights From the API-CAT Randomized Trial
Authors: Isabelle Mahé, Céline Chapelle, Marc Righini, Grégoire Le Gal, Frederikus A. Klok, Giancarlo Agnelli, Francis Cajfinger, Marie-Antoinette Sevestre, Philippe A. Grenier, Jérôme Alexandre, Francis Couturaud, Patrick Mismetti, Silvy Laporte, Jean Chidiac
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 9, 2026, 23:59Ana Pedrero Gil: Is Coagulopathy with Fibrinolysis Present in All Obstetric Hemorrhages?
-
Oct 9, 2026, 23:57Exploring the Psychosocial Needs of People with Bleeding Disorders in Kyrgyzstan – EAHAD
-
Oct 9, 2026, 23:53Bernard Slater Jr.: Serving on the Advisory Council for the NBDF West Virginia Chapter
-
Oct 9, 2026, 23:53Aurelio Maggio: Thalassemia Reports Real-Time Impact Factor Rises to 1.760
-
Oct 9, 2026, 23:52Stronger Connections, Stronger Organizations – World Federation of Hemophilia
-
Oct 9, 2026, 23:46Samuel Misiani Mbunya: Advancing Sickle Cell Care Through Collaboration at the 21st ASCAT Conference
-
Oct 9, 2026, 23:42Hadeel Swed: My First First-Author Publication in Thrombosis Research
-
Oct 9, 2026, 23:38Micheal Avoseh: Exploring Nanoparticle-Based Therapies for Thrombosis and Vascular Inflammation
-
Oct 9, 2026, 16:23David Boone: Distinguishing Stroke Prevention from Rhythm Control in Atrial Fibrillation